Question

Which of the following is a PCSK9 inhibitor? 

• A. Evolocumab
• B. Ezetimibe
• C. Bempedoic acid
• D. Clofibrate

Answer 1

The Correct Option is A

In the field of pharmacology, recognizing drug classes and their mechanisms of action is crucial. PCSK9 inhibitors are a class of drugs that target the PCSK9 protein, which plays a significant role in the degradation of LDL receptors, hence affecting cholesterol levels in the body. Identifying a PCSK9 inhibitor requires knowledge of these drugs. Among the options provided:

• Evolocumab: This is indeed a PCSK9 inhibitor. It works by inhibiting the function of the PCSK9 protein, leading to increased recycling of LDL receptors and subsequently lowering LDL cholesterol levels.
• Ezetimibe: This drug is not a PCSK9 inhibitor. Instead, it acts by reducing the absorption of cholesterol in the small intestine.
• Bempedoic acid: This is also not a PCSK9 inhibitor. It lowers cholesterol by inhibiting ATP citrate lyase, an enzyme involved in cholesterol synthesis.
• Clofibrate: This drug is a fibrate and works by activating peroxisome proliferator-activated receptors (PPARs), which is unrelated to PCSK9 inhibition.

Thus, the correct answer is Evolocumab. It is the drug among the given options that functions as a PCSK9 inhibitor.